The Farawave NAV ablation catheter and the Faraview software are compatible exclusively with Boston Scientific’s existing cardiac mapping technology, including the Opal HDx Mapping System. Image Credit: Michael Vi / Shutterstock.

Boston Scientific has launched its Farawave NAV ablation catheter and Faraview software after the US Food and Drug Administration (FDA) approved the two devices.

The technologies are used in conjunction with the company’s Farapulse pulsed field ablation (PFA) system to provide visualisation for cardiac ablation procedures, a treatment for atrial fibrillation (AFib). The Farapulse PFA system received FDA approval in January 2024.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Boston Scientific noted that “these technologies are compatible exclusively with the company’s existing cardiac mapping technology including the Opal HDx Mapping System”. Additionally, the Farawave NAV ablation catheter improves on the current Farawave catheter by adding magnetic navigation capabilities, which allows physicians to see where pulsed fields have been applied and visualise cumulative therapy delivery to guide the ablation strategy.

The Farawave NAV ablation catheter also allows physicians to track the delivery of PFA through automated tagging technology by showing the approximate pulsed field locations within the heart, based on the catheter’s position.

“In clinical use, the Faraview software and the Farawave NAV ablation catheter produced detailed cardiac maps that could improve guidance, limit fluoroscopy times and assist physicians in assessing the location of energy delivered during PFA procedures,” said Dr Vivek Reddy, director of electrophysiology, Mount Sinai Fuster Heart Hospital.

“The addition of navigation and visualisation capabilities to the Farapulse PFA System could aid workflow efficiency and enhance the treatment physicians can provide to patients living with AFib.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Farapulse’s primary competitor is Medtronic’s PulseSelect, the only other FDA-approved PFA device. Despite Medtronic gaining FDA approval first, there is a stronger physician preference for Boston Scientific’s device. According to GlobalData analysis, Boston Scientific has acquired more than 74% of shares from Medtronic in the PFA space.